ChinaBio  
ChinaBio® 的故事始于一次旅行... 2006年11月，我们的创始人Greg Scott先生第一次到访中国。他为赴一次商务会面来到了上海张江高科技园。这次会议后，他简要走访了这个占地面积25km2的园区，看到了罗氏、辉瑞、葛兰素史克、礼来以及200多家早期生物技术公司，他就坚信自己将再次来到中国。在美国拥有超过10年生物技术行业天使投资经验的他相信中国将有"大事"发生，他决心一探究竟。

因此2007年1月下旬，他再次来到中国，计划停留一周时间，只安排了2场会议。但到这周结束时他已经进行了30多次会议，他心里已经播下了ChinaBio® 的种子。到了4月，ChinaBio® 在张江高科技园区药谷大厦开设了办公室，招进了第一位员工。当时他常听说鲜有人对中国的早期生物技术/医药技术感兴趣，而他就成了这少数人之一，并且在与数家极具发展潜力的公司合作之后，他更是热情高涨。

世界发现中国生物技术

2007年8月，无锡姚明康德上市了，紧随其后的是其他几家中国生物技术企业的首次公开募股。整个世界突然意识到中国也有生物技术产业，并想了解更多，然后开始纷纷涌至中国。2008年初，我们搬到了对面更大的办公室，公司团队也从2名扩大到10名全职和数名兼职员工。Scott先生还接受了中央电视台英文国际频道及几家电台和互联网节目的采访。

到2010年底， ChinaBio® 已经在中国举办了的15次重大会议，包括10次ChinaBio®创业投资论坛和两届ChinaBio®合作论坛，并在旧金山和布鲁塞尔举办参会人数近4000人的“中国节”活动。2011年我们计划主办5次主要会议，包括我们的首届ChinaBio® 领导人高尔夫年会。（详情参见“会议预告”栏目）

我们与一些包括罗氏、辉瑞及Life Technologies在内的全球最具影响力的医药和生物技术公司进行了合作，帮助中国生物医药公司融资逾4亿美元。我们的公司内部调研团队密切追踪中国生物技术行业的商业动态，包括新技术研发、临床实验活动、风险投资、并购及首募活动等。这些信息帮助我们和我们的客户深入了解行业发展动向并准确预测中国对未来全球生物医药产业的影响。 

Scott先生已经是以上海为家，乐享中国的无限活力而放弃圣地亚哥的阳光和沙滩。中国的事务发展之快仍让他惊喜不已。

It Begins with a Vacation

The story of ChinaBio® starts with a vacation... In November 2006, our founder, Greg Scott, visited China for the first time.  He had arranged to have one business meeting while he was in Shanghai at Zhangjiang Hi-Tech Park.  From that single meeting, and a brief tour of the 25 sq. km Park where he saw Roche, Pfizer, GSK, Lilly, and over 200 early-stage biotech companies, he knew he would be coming back to China.  His 10-years of experience as an angel investor in biotech in the US led him to believe that there was something "big" happening in China, and he had to find out more.

So in late January 2007, he returned for one week with only two scheduled meetings.  By the end of the week and over 30 meetings, the seeds of ChinaBio® were sown.  By April, ChinaBio's offices were open in the Biotech VC Plaza building in Zhangjiang Hi-Tech Park, and the first staff was hired.  While often told he was one of the very few interested in early-stage biotech/medtech in China, his interest remained high as he worked with several promising companies.

The World Discovers China Biotech

Then, in August 2007, WuXi PharmaTech went public, quickly followed by several other China biotech IPOs.  Suddenly the world knew there was a biotech industry in China and wanted to know more and began beating a path to ChinaBio's door. By early 2008, ChinaBio had moved to larger offices and expanded the staff from two to six full time and three part time members.  Mr. Scott had also been interviewed on CCTV and several radio and internet shows.

By the end of 2010, ChinaBio® had organized over 15 major conferences in China, including 10 ChinaBio® Investor Forums, two ChinaBio® Partnering Forums, and China Day events in San Francisco and Brussels, hosting a combined total of nearly 4000 attendees.  For 2011, ChinaBio is planning five major events, including our new ChinaBio®Leadership Retreat.  (See .)

ChinaBio® has also worked with some of the world's most respected life science companies, including Pfizer, Roche Diagnostics and Life Technologies, and helped China biomedical companies raise over $400M US.  Our in-house research team tracks China's biotech industry including novel technology development, clinical trial activity, VC investments, IPOs and M&A and partnering activity.  This information gives us and our clients critical insights into the direction of the industry and how China will impact the future of the global biopharma industry.

Mr. Scott now makes Shanghai his home, trading the sunshine and beaches of San Diego for the vitality of China.  It surprises even him how quickly things can move in China.